2438 Results for "

decrease

" in MedChemExpress (MCE) Product Catalog:
Products (2438)

2438 Results for "decrease" in MCE Product Catalog:

Referencia número: HY-130272
No. CAS: 2387506-35-4
Target:  

Drug Derivative

Áreas de investigación:  

Cardiovascular Disease

Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .
loading...
    loading...
Referencia número: HY-13315AR
No. CAS: 158966-92-8
Synonyms: MK0476 free base (Standard)
Áreas de investigación:  

Inflammation/Immunology

Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .
loading...
    loading...
Referencia número: HY-133829
No. CAS: 75176-37-3
Zofenoprilat is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 1.7 nM. Zofenoprilat exerts cardioprotective and renoprotective effects by inhibiting angiotensin II expression and lowering blood pressure. Zofenoprilat promotes NO production and reduces endothelin-1 (ET-1) expression. Zofenoprilat decreases TNFα-induced ROS production and protects vascular endothelial function. Zofenoprilat regulates oxidative stress-related molecules and possesses antioxidant activity. Zofenoprilat can be used in studies related to hypertension and congestive heart failure .
loading...
    loading...
Referencia número: HY-134043
No. CAS: 16289-13-7
Synonyms: Chlorthalidone EP Impurity G
Target:  

Carbonic Anhydrase

Áreas de investigación:  

Cardiovascular Disease

Chlorthalidone Impurity G (Chlorthalidone EP Impurity G) is a potential impurity found in commercial preparations of chlorthalidone with moderate antihypertensive effects. Chlorthalidone is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal tubule of the kidney, thereby preventing sodium and chloride reabsorption, resulting in decreased plasma volume and cardiac output. It also inhibits carbonic anhydrase (CA), including isoenzymes CAVB, VII, IX, XII, and XIII (Kis=2.8-23 nM) and to a lesser extent CAI, CAII, IV, VA, and VI (Ki=138-1,347 nM), mediating vasodilatory activity.
loading...
    loading...
Referencia número: HY-13468A
No. CAS: 819812-18-5
Áreas de investigación:  

Cancer

KW-2478 hydrochloride is an HSP90 inhibitor (IC50 = 3.8 nM). KW-2478 hydrochloride inhibits the growth and induces apoptosis in chronic myeloid leukemia (CML) cells and liver cancer cells. KW-2478 hydrochloride weakens the BCR/ABL and MAPK signaling pathways, leading to increased p27 and p21 expression and decreased cyclin B1 expression. KW-2478 hydrochloride downregulates STAT3 expression. KW-2478 hydrochloride may be used in research on cancers such as CML and liver cancer .
loading...
    loading...
Referencia número: HY-136258
No. CAS: 2250025-94-4
Target:  

nAChR

Áreas de investigación:  

Neurological Disease

nAChR agonist CMPI hydrochloride is a potent and selective positive allosteric modulator (PAM) of nAChR containing a α4:α4 subunit interface. nAChR agonist CMPI hydrochloride enhances the response of (α4)3(β2)2 nAChR to ACh (10 µM) with an EC50 of 0.26 µM. nAChR agonist CMPI hydrochloride has potential for the research of nicotine dependence and many neuropsychiatric conditions associated with decreased brain cholinergic activity .
loading...
    loading...
Referencia número: HY-136704
No. CAS: 1832646-52-2
Pureza:  98.5%
Target:  

Glutaminase

Áreas de investigación:  

Cancer

GLS1 Inhibitor-1 is an orally active, allosteric, selective GLS1 inhibitor with an IC50 of 0.021 µM for GLS1 and an IC50 of 0.051 µM for the GLS1 GAC splice variant. GLS1 Inhibitor-1 increases glutamine and decreases glutamate and aspartate. GLS1 Inhibitor-1 exhibits anticancer activity against non-small cell lung cancer. GLS1 Inhibitor-1 can be used for research on non-small cell lung cancer .
loading...
    loading...
Referencia número: HY-137135A
No. CAS: 1465-77-6
Pureza:  95%
Cantharidic acid disodium is a Cantharidin (HY-N0209) analog, anticancer agent, and selective Ser/thr phosphatase 1 and 2A inhibitor. Cantharidic acid disodium induces ROS, Mitochondrial dysfunction, LDH release, cell cycle arrest, and Apoptosis. Cantharidic acid disodium decreases Nrf2, HO-1, and GPX4, and reduces PCNA, MMP2, and MMP9. Cantharidic acid disodium can be used in research on colorectal cancer, hepatocellular carcinoma, oral squamous cell carcinoma, and adenocarcinoma .
loading...
    loading...
Referencia número: HY-139994
No. CAS: 2820169-36-4
Synonyms: XP
Áreas de investigación:  

Metabolic Disease

XN methyl pyrazole (XP) is an orally active, blood-brain barrier permeable uncoupler/proton carrier. XN methyl pyrazole uncouples oxidative phosphorylation, depolarizes mitochondrial transmembrane potential, increases energy expenditure, spontaneous activity levels, and cortical inosine monophosphate levels. XN methyl pyrazole reduces plasma purine and energy metabolite levels, improves glucose tolerance, and decreases weight gain, while avoiding potential estrogenic side effects. XN methyl pyrazole can be used in studies related to diet-induced obesity and insulin resistance .
loading...
    loading...
Referencia número: HY-14370
No. CAS: 948840-25-3
Pureza:  98.31%
Target:  

LPL Receptor

Áreas de investigación:  

Others Inflammation/Immunology

LX2931 is an inhibitor of Sphingosine 1-Phosphate Lyase (S1PL). LX2931 works by increasing levels of S1P inside and outside the cell. The decrease in S1PL activity leads to a significant increase in S1P content in tissues, especially in lymphoid tissues which may lead to a restricted exodus of lymphocytes from secondary immune tissues, resulting in lymphocytopenic and immunosuppressive effects in the peripheral circulation. LX2931 can be used in research for the study of autoimmune diseases, especially rheumatoid arthritis .
loading...
    loading...
Referencia número: HY-146461
Áreas de investigación:  

Cancer

Anticancer agent 58 (compound 16) has inhibitory activity against kinds of cancer cell lines, especially in A549 and T24 with IC50s of 0.6 μM and 0.7 μM, respectively. Anticancer agent 58 induces apoptosis by activating caspase 3/8/9 activity, and induces an increase of Ca 2+ and ROS in cancer cells. Anticancer agent 58 significantly decreases mitochondrial membrane potential. Anticancer agent 58 can suppress tumor growth in T24 mouse xenograft model .
loading...
    loading...
Referencia número: HY-150364
No. CAS: 2953012-32-1
Synonyms: RGLS8429; RG1015
Target:  

MicroRNA

Áreas de investigación:  

Metabolic Disease

Farabursen (RGLS8429; RG1015) is a blood-brain barrier-permeable miR-17 inhibitor. Farabursen derepresses Pkd1 and Pkd2, the target genes of miR-17, increases the levels of PC1 and PC2, and reduces cyst growth. Farabursen decreases renal cyst growth, kidney weight-to-body weight ratio, cyst index, proliferation index, and blood urea nitrogen levels in mouse models. Farabursen is applicable to research related to autosomal dominant polycystic kidney disease .
loading...
    loading...
Referencia número: HY-152251
No. CAS: 928892-60-8
Áreas de investigación:  

Inflammation/Immunology

CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with Kis of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .
loading...
    loading...
Referencia número: HY-153369
No. CAS: 1609342-18-8
Synonyms: BAY 1165747
Target:  

Guanylate Cyclase

Áreas de investigación:  

Cardiovascular Disease Neurological Disease

BAY-747 (BAY 1165747) is an orally active and brain-penetrant stimulator of soluble guanylate cyclase (sGC). BAY-747 reverses L-NAME induced memory impairments and enhances cognition of rats in the object location task (OLT). BAY-747 also decreases blood pressure in both conscious normotensive and spontaneously hypertensive rats (SHR). BAY-747 improves function of the skeletal muscle associated with Duchenne muscular dystrophy (DMD) in mdx/mTRG2 mice model .
loading...
    loading...
Referencia número: HY-153491
No. CAS: 2097587-83-0
Synonyms: ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx
Áreas de investigación:  

Cardiovascular Disease

Olezarsen (ISIS 678354; IONIS-APOCIII-LRx) is a GalNAc3-conjugated antisense oligonucleotide. Olezarsen binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen decreases plasma levels of triglycerides, apolipoprotein B and non-high-density lipoprotein cholesterol. Olezarsen is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .
loading...
    loading...
Referencia número: HY-156800
No. CAS: 2232878-43-0
Pureza:  99.97%
Target:  

Phospholipase

Áreas de investigación:  

Neurological Disease

PDDC is an orally active and blood-brain barrier-penetrant nSMase2 inhibitor. PDDC reduces ceramide production and extracellular vesicle biogenesis/release through enzyme inhibition (IC50 300 nM). PDDC reduces IL-1β-induced release of plasma extracellular vesicles from neurons, oligodendrocytes, and activated microglia, and decreases the ratio of CD11b-positive/IB4-positive extracellular vesicles. PDDC can be used in research related to acute brain injury .
loading...
    loading...
Referencia número: HY-158342
No. CAS: 3061498-57-2
Pureza:  99.82%
Target:  

PROTACs YAP

Áreas de investigación:  

Cancer

PROTAC TEAD degrader-1 is a TEAD2 degrader and antiproliferative agent with selective activity toward TEAD2 relative to other TEAD family members. PROTAC TEAD degrader-1 relies on CRBN and the proteasome system for TEAD2 degradation; disruption of CRBN binding attenuates this activity. PROTAC TEAD degrader-1 decreases expression of YAP target genes CYR61 and CTGF. PROTAC TEAD degrader-1 can be used for the research of NF2-deficient cancer .
loading...
    loading...
MDM4-targeting ASO sodium
0 Images
MDM4-targeting ASO (sodium)
Referencia número: HY-158830
MDM4-targeting ASO sodium is a 25mer antisense oligonucleotide targeting MDM4. MDM4-targeting ASO sodium induced exon 6 skipping, leading to nonsense-mediated decay of the mRNA transcript that excludes exon-6. In multiple human melanoma cell lines and in melanoma patient-derived xenograft (PDX) mouse models, MDM4-targeting ASO-mediated skipping of exon 6 decreased MDM4 abundance, inhibited melanoma growth, and enhanced sensitivity to MAPK-targeting therapeutics.
loading...
    loading...
Referencia número: HY-159152
No. CAS: 2226535-25-5
Áreas de investigación:  

Neurological Disease

PQM-164 (Compound 3e) has antioxidant activity (IC50: 0.93 μM for DPPH radical). PQM-164 shows anti-inflammatory activity against 6-OHDA (HY-B1081A)-induced neuronal damage in activated microglial cells. PQM-164 decreases the accumulation of α-synuclein. PQM-164 promotes nuclear translocation of Nrf2 and its transcriptional activity. PQM-164 can be used for research of Parkinson’s disease .
loading...
    loading...
Referencia número: HY-160477
No. CAS: 300713-88-6
Target:  

PIKfyve NF-κB IKK

Áreas de investigación:  

Inflammation/Immunology

DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with oral activity with an estimated KD constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .
loading...
    loading...